top of page
High-Grade NET Resources (Twitter Header).png

High Grade Neuroendocrine Tumor (NET)
and Neuroendocrine Carcinoma (NEC) Resources

Learn more about clinical trials specifically for High Grade, Grade 3 (G3) Neuroendocrine Tumor (NET) and Neuroendocrine Carcinoma (NEC).  

WATCH

LISTEN

Extrapulmonary neuroendocrine carcinoma (EP-NEC) is a rare and complex cancer that can be difficult to recognise, diagnose, and treat. This short video helps patients and care partners understand the disease, including what to expect from diagnosis and treatment, the urgency needed, and where support is available. It is designed to help patients and their families navigate this challenging condition. 

​

Click here for more information >>>

In this video podcast by COR2ED, Neuroendocrine Patient Advocate Susan Meckler-Plummer joins Medical Oncologist Dr. Aman Chauhan to discuss extra-pulmonary neuroendocrine carcinomas (EP-NECs).

 

Click here for more information >>>

VOICE epNEC Patient Survey 

November, 2025

​

Take part in this online research survey to help better understand the real-life experiences of people living with neuroendocrine carcinoma. The goal of this study is to learn directly from patients so we can help improve future care, resources, and support for the NET community.

​

This survey takes approximately 30 minutes to complete, and eligible participants will receive an $80 Amazon gift card as a thank you for their time. Participation is completely voluntary, and all responses will remain confidential.

PATIENT STORY

A patient living and thriving with high grade neuroendocrine cancer shares her inspiring story.

FACEBOOK GROUP

For more information & and support, contact high grade patient advocate Susan Meckler Plummer, who supported her late husband with NEC.

Susan Meckler Plummer

609-731-0322 

susan@netsmission.org

NEUROENDOCRINE CANCER FOUNDATION
 
Mailing Address:
PO BOX 370466
DENVER, CO 80237

info@ncf.net
​
  • Facebook
  • Instagram
  • X
  • Youtube
  • LinkedIn

© 2025 by Neuroendocrine Cancer Foundation

bottom of page